Spots Global Cancer Trial Database for glutaminase
Every month we try and update this database with for glutaminase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of the Glutaminase Inhibitor CB-839 in Leukemia | NCT02071927 | Acute Myeloid L... Acute Lymphocyt... | CB-839 CB-Aza | 18 Years - | Calithera Biosciences, Inc | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | NCT02071888 | Non-Hodgkin's L... Multiple Myelom... Waldenstrom's M... Other B-cell NH... T-cell NHL | CB-839 CB-839 and low ... CB-839, pomalid... | 18 Years - | Calithera Biosciences, Inc | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| Study of the Glutaminase Inhibitor CB-839 in Leukemia | NCT02071927 | Acute Myeloid L... Acute Lymphocyt... | CB-839 CB-Aza | 18 Years - | Calithera Biosciences, Inc | |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | NCT03057600 | Triple Negative... TNBC - Triple-N... | Paclitaxel CB-839 | 18 Years - | Calithera Biosciences, Inc | |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | NCT03163667 | Clear Cell Rena... | Placebo CB-839 everolimus | 18 Years - | Calithera Biosciences, Inc | |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | NCT03163667 | Clear Cell Rena... | Placebo CB-839 everolimus | 18 Years - | Calithera Biosciences, Inc | |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | NCT02071862 | Solid Tumors Triple-Negative... Non Small Cell ... Renal Cell Carc... Mesothelioma Fumarate Hydrat... Succinate Dehyd... Succinate Dehyd... Tumors Harborin... Tumors Harborin... | CB-839 Pac-CB CBE CB-Erl CBD CB-Cabo | 18 Years - | Calithera Biosciences, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
